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Abstract
Objective—To describe the health and
economic consequences of smoking
model, a user friendly, web based tool,
designed to estimate the health and
economic outcomes associated with
smoking and the benefits of smoking
cessation.
Results—An overview of the development
of the model equations and user interface
is given, and data from the UK are
presented as an example of the model out-
puts. These results show that a typical
smoking cessation strategy costs approxi-
mately £1200 per life year saved and
£22 000 per death averted.
Conclusions—The model successfully
captures the complexity required to
model smoking behaviour and associated
mortality, morbidity, and health care
costs. Furthermore, the interface provides
the results in a simple and flexible way so
as to be useful to a variety of audiences
and to simulate a variety of smoking
cessation methods.
(Tobacco Control 2001;10:55–61)
Keywords: consequences of smoking; model; health
consequences; economic consequences
Tobacco use is associated with a number of
chronic or acute diseases and enormous
societal costs. Although the number of people
who die or suVer illness because of its use is the
best measure of the burden of tobacco, the cost
to society must also be measured in terms of
economic loss. Tobacco use drains economies
of billions of dollars in health care costs and
lost productivity each year. As an example,
smoking related diseases cost the National
Health Service in England between £1.4 and
£1.5 billion annually,1 yet tobacco addiction is
a treatable medical condition. For a relatively
small initial outlay, smoking cessation
interventions result in health gains, which in
the long term save lives and reduce the cost of
health care for smoking related diseases, releas-
ing resources for other health care
programmes.
The methodology described in this paper
suggests one approach to developing an epide-
miological model for smoking related diseases
and the implications of smoking cessation.
This methodology was driven by the needs of
the end users and the need for a realistic and
robust model. The health and economic
consequences of smoking (HECOS) model
captures the complexity required to model
smoking behaviour and associated morbidity,
mortality, and costs. This is shown within the
paper using data from the UK as an example.
The model interface presents these results in a
simple, easy-to-use way, allowing diVerent sce-
narios and combinations of smoking cessation
aids to be considered. Users can select
diVerent strategies by changing key values. In
this way, the model is flexible enough to be
useful to a variety of decision makers.
Objectives
The objective of this work was to develop an
interactive software tool that would be widely
accessible and applicable for use by health care
payers, government policy makers, and other
health care organisations in a variety of
countries. A key purpose of the model is to
show the health and economic burden that
smoking related diseases place on health care
systems, in addition to showing the potential
disease cases averted and the reduction in the
smoking related disease costs resulting from
successful smoking cessation programmes.
The model was commissioned by Glaxo Well-
come for the Lewin Group and oVered for use
by the World Health Organization (WHO)
“European partnership project to reduce
tobacco dependence”. The model thus
currently includes the four target countries of
the WHO European partnership project (UK,
France, Germany, and Poland), in addition to
other European Union countries, as well as
Australia, China, Czech Republic, Hungary,
Mexico, New Zealand, Norway, and Ukraine.
The purpose of this paper is to outline the
stages in the development of the HECOS
model and the methodology used to construct
the model equations. Additionally, data from
the UK are presented as an example of
HECOS outputs.
Overview of model development
To model the burden of smoking in a given
population, the relation between diVerent
smoking behaviours and the risk of smoking
related disease needs to be considered. There-
fore, the first stage of the development of the
HECOS model was a review of available litera-
ture and consultations with appropriate
specialists to obtain a comprehensive
understanding of the modelling problem.
When there is no overlap between successive
generations, population growth can be
modelled in discrete steps. Even if a population
varies continuously with time, it can be
approximated by a discrete system by
considering the total population at fixed time
intervals. If the time between successive
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generations is a fixed time step, say t, then the
population at a time t+1, denoted by Nt+1, can
be related to the population at time t, denoted
by Nt, using the equation:
where f (Nt) represents, in general, a
non-linear function of Nt. Discrete diVerence
equations such as equation 1 are widely
studied and have a broad range of applications,
particularly in the study of population dynam-
ics.2 3 These simple equations can exhibit com-
plex behaviour4 and are usually impossible to
solve analytically. The advantage of presenting
the model equations in this way is that the vari-
ables for future time steps are stated explicitly,
in terms of variables from previous time steps.
Therefore, it is straightforward to evaluate such
equations by using equation 1 recursively.
Markov models are commonly used in
health economics to model diseases or
interventions that display cyclic behaviour.
Markov models are particularly suited to mod-
elling chronic disease, where patients
experience disease progression over time.5–7
These models use transition probabilities,
which give the likelihood of moving to a
particular state in the next cycle, given the
present state in the current cycle. A Markov
model can be written as a set of discrete diVer-
ence equations of the form:
where A(t) is the transition probability
matrix.
The functional form of equation 1 is more
comprehensive than the Markov system given
in equation 2, since it is not restricted to tran-
sition probabilities or even first order terms. By
considering a broader range of functions in our
model, the switch from one state to another is
not just time driven, but can be dependent
upon other factors. As with Markov systems,
these equations are based on the assumption of
“no memory”, in that the transition from one
model state to another depends entirely on the
current state and is not influenced by events in
previous time steps. For example, the
likelihood that a smoker will make an attempt
to quit smoking may depend on the number of
previous quit attempts. While this is a
limitation of the model, data pertaining to the
impact of prior events is not widely available
and a more complex model, such as a system of
non-linear diVerential equations, would
certainly decrease the performance of the
model interface. In general, a pseudo-Markov
model provides a simple and eYcient way of
modelling the costs and outcomes resulting
from health care interventions, particularly for
progressive, chronic diseases.5 6
The key activity in such modelling problems
is in determining the most appropriate form of
the function f ( Nt ). This function must be
carefully chosen in order to capture known or
observed behaviour in the study population.
Hence, it is good modelling practice to have a
full understanding of the modelling problem
before attempting to define the model
equations. More details of the model
assumptions are given in appendix 1 at the end
of this article.
CONSTRUCTION OF THE SMOKING MODEL USER
INTERFACE
The interface was chosen after examining the
needs of the end user and accessibility to the
model interface, among other considerations.
It was a requirement that the model interface
be easy to use and should be made available
over the internet. In addition, the model was to
be available as a stand alone application, which
did not require any special software to support
the programme. Further requirements were
that the model could be extended at any stage
to include additional calculations or extra
countries, that key variables could be altered by
the user, and that the model should be robust
in order to support multiple users and large
data sets.
Therefore, the interface was developed using
a Microsoft Visual Basic 6 front-end with a
Microsoft Access 97 database back end. For
the web version, the system was constructed
around a Microsoft Visual Basic WebClass.
This consists of an ASP page, which makes
calls to various ActiveX DLLs. This handles
user interactions within the interface, as well as
calculation of the model equations and
generating outputs in the form of tables and
graphs. Further to this, the model equations
were translated into a spreadsheet format
(Microsoft Excel 97), which provided a testing
environment and facilitated the sensitivity
analysis.
The advantage of this approach is that a
powerful yet flexible application can be
produced in a relatively short development
time. The stand alone model can be run on
most standard computer systems without the
need for any additional software support. The
web version of the model is hosted by WHO8
and a standard web browser tool such as
Microsoft Internet Explorer 4 will allow access
to the model.
Results
The model interface allows the user to amend
some key parameters such as the cost, eYcacy,
and percentage using each of the diVerent
smoking cessation methods, the initial number
in the model cohort, the discount rate, etc. For
the purpose of this paper, the default results for
the UK cohort of smokers are presented to
demonstrate the possible outputs of the model.
For details of the sources used for the default
UK data, see appendix 2 on eTC (www.tobac-
cocontrol.com). In order to determine the
validity and comparability of our results with
those obtained by other researchers, further
calculations were made (not shown in model
interface), which were directly compared with
published studies.
Tables 1 and 2 show the number of cases of
morbidity at any given year and the cumulative
number of deaths associated with smoking
related disease. It can be seen that smoking
related diseases in the UK account for over five
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million cases of smoking related morbidity at
20 years and 2.4 million deaths over the 20
year period.
The model predicts that 79 000 smokers will
die from one of five smoking related diseases in
the first year alone. Table 3 shows a breakdown
of these deaths by disease and compares these
results to those from Callum.9
After 20 years, it is estimated that 56% of the
smoking population in the UK will be aVected
by or will have died from a smoking related ill-
ness (7.5 million out of 13.3 million). This is in
agreement with UK/US studies, which show
that about half of all smokers are eventually
killed by smoking.10 The model also predicts
that in 20 years 18% of the current smoking
population will have died from a smoking
related disease (2.4 million out of 13.3
million). As a comparison, using the figures
from Callum9 given above, and assuming that
the annual number of deaths stay the same over
time, approximately 1.8 million smokers would
die in the 20 years. The model prediction takes
into account the increase in the risk of morbid-
ity and mortality as the cohort ages.
Table 4 illustrates that after 20 years, the
cumulative cost of smoking related morbidity is
approximately £28.3 billion, when discounted
at 6%, which is the discount rate recom-
mended by the UK government.11 These costs
are direct medical costs only and do not take
into account lost productivity costs such as
absenteeism from work or patient costs. The
current model costs represent scaled 1999
prices. Using default data for the UK for a
cohort of smokers, table 5 shows the total cost
of treating smoking related disease in the first
year of the model compared to the results from
Parrott and colleagues.1
There are a variety of methods used when
attempting to quit smoking (for example, phar-
macological treatment, group counselling,
“willpower”). Each method has a diVerent cost
and a diVerent chance of success. In this
model, the user can use a combination of
methods to form a smoking cessation interven-
tion strategy. Table 6 shows the default
smoking cessation strategy employed for the
analysis of the UK smoking population. The
default values for treatment eYcacy were taken
from the average of those given in a number of
published studies.12–15 The default values for
usage of the interventions were taken from
Parrott and colleagues.1
A smoking cessation strategy consisting of a
combination of pharmacological treatment,
general practitioner advice, etc, as shown in
table 6, has a total cost of £103 575 877. From
table 7, it can be seen that this smoking cessa-
tion strategy costs approximately £1200 per
life year saved and £22 000 per death averted.
An article published by Tengs and colleagues
reports cost-eVectiveness estimates for more
than 500 life saving interventions, including
smoking cessation therapies, which are shown
to be more cost-eVective than many other dis-
ease interventions.16 As a comparison with the
HECOS model results, the cost per life year
saved of smoking cessation advice as given in
Tengs and colleagues ranges from $990 to
$9800 (approximately £600–£6000).
Table 1 Number of cases of morbidity associated with
smoking related disease in the UK
2 years 5 years 10 years 20 years
COPD 1794571 1965191 2364792 3236776
Asthma 487351 508018 544122 615259
CHD 455679 532568 626238 651600
Stroke 90602 94325 109725 127293
Lung cancer 35436 43471 64384 72533
LBW 97653 189524 331006 571003
Total 2961292 3333097 4040265 5274464
COPD, chronic obstructive pulmonary disease; CHD,
coronary heart disease; LBW, low birth weight pregnancy.
Table 2 Cumulative number of cases of mortality
associated with smoking related disease in the UK
2 years 5 years 10 years 20 years
COPD 38153 104048 241912 653893
Asthma 56 139 281 568
CHD 61317 167334 390627 970760
Stroke 19162 48966 106199 257607
Lung cancer 37728 93469 220671 548060
LBW 0 0 0 0
Total 156417 413956 959689 2430888
Table 3 Comparative mortality and morbidity figures
COPD Asthma CHD Stroke Lung cancer LBW
Model results 18557 28 29977 9602 20583 0
Figures from Callum6 24400 – 26400 7300 30600 –
Table 4 Cumulative health care costs associated with smoking related disease in the UK
2 years 5 years 10 years 20 years
COPD £592611005 £1417270132 £2672049381 £4782735270
Asthma £289938624 £679245194 £1223108139 £2002533494
CHD £967977730 £2408706686 £4631761071 £7852225683
Stroke £838787789 £1947015096 £3575206478 £6100033102
Lung cancer £228703959 £532745049 £1101550176 £2063551665
LBW £1417733715 £2560759463 £3960509932 £5524342670
Total £4335752822 £9545741620 £17164185178 £28325421884
Table 5 Comparative health care costs
Health care cost per
case from model
Total annual health care cost
from model at 1999 prices
Total annual health care cost from
Parrott et al1 at 1991 prices
COPD £172.00 £301412486 £236000000
Asthma £308.28 £148200759 –
CHD £1127.49 £483285349 £364000000
Stroke £4749.50 £432831903 £345000000
Lung cancer £3044.40 £126930451 £86000000
LBW £14790.52 £974284,051 –
Table 6 Smoking cessation intervention default strategy
for UK
Smoking cessation method Cost
EYcacy
(%)
Usage
(Parrott et al.1)
Pharmacological treatment £77.92 13 25
Gneral practitioner advice £1.84 3 10
Group therapy £91.87 9 2
No intervention/willpower £0.00 1 63
Average £21.50 4.4 100
Table 7 Potential impact of smoking cessation strategy in
the UK
Year
Total life
years saved
Total deaths
averted
Reduction in cost of
smoking related disease
2 503 503 £4583295
5 4930 1961 £15921039
10 21967 4350 £28933685
20 85473 7533 £36945579
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SENSITIVITY ANALYSIS
An extensive sensitivity analysis was performed
to ensure that the model was robust and that
small changes in key model parameters did not
lead to a large variation in the results. A brief
description of the analyses follows.
Firstly, the annual percentage of smokers
who make an attempt to quit smoking was
considered. The default for the UK, as
obtained from Bridgwood,17 was increased in
increments of 10% from 36% up to 96% and
the result at 20 years was compared. The aver-
age eVect of this increase was a reduction of
3675 in the number of cases of morbidity, a
decrease in health care spending for smoking
related disease of £35 million, and a reduction
in smoking related mortality of 10 239 cases.
The cost of smoking cessation intervention per
death averted increases on average by £138 per
increment over the same range, though the cost
of smoking cessation intervention per life year
saved is reduced on average by £123.
To examine the eVect that uncertainty in the
usage or eYcacy of individual cessation
treatments has on the overall results, the
average eYcacy rate was varied from 4.4% to
34.4%, in increments of 5%. An eYcacy
greater than 34.4% was assumed to be un-
achievable given the treatments currently avail-
able. A 5% change in the average eYcacy of the
smoking cessation strategy leads to an average
change of 0.05% in cases of morbidity
(approximately 2551 cases). Furthermore, this
achieves an average 0.4% change in cases of
mortality (8644 cases) and 0.1% change in the
cost of health care (£42.3 million). By increas-
ing the eYcacy from 4.4% to 34.4%, the cessa-
tion intervention cost per death averted and
cost per life year saved are decreased by 87%
(£12 006 and £1058, respectively).
In the model, the percentage of long term
quitters relapsing was given as a fixed rate per
year.18 However, this may overstate the number
of long term quitters who recommence
smoking as, intuitively, the relapse rate should
decrease the longer a person refrains from
smoking. Hence, the relapse rate was reduced,
in increments of 1%, from 6.9% to 0%. A
decrease of 1% reduces the number of cases of
morbidity over 20 years by an average of 2658,
which decreases health care spending for
smoking related disease by an average of £13.6
million and reduces smoking related mortality
by an average of 5623. Furthermore, the cost
of smoking cessation intervention per death
averted and cost per life year saved decreases
by an average of £974 and £64, respectively.
Forecasting costs in the future is subject to
some degree of uncertainty, particularly as the
economic climate and prospective improve-
ments in health care may result in a decrease or
increase in future costs. The health care costs
in this model were discounted, though
outcomes were not. The default discount rate
for the UK was taken to be 6% as per UK gov-
ernment recommendations.11 This value was
varied from 0% through to 10%. A 1% change
in the discount rate results in an average
change of 8% in the total health care costs.
Discussion
The HECOS model is a useful, friendly,
flexible, and easily accessible interface. It is
unique in that both the health benefits (for
example, life years saved) and changes in
smoking related health care costs can be simu-
lated over time for the individuals in a popula-
tion. Hence, the model estimates both health
and economic consequences of smoking and
smoking cessation.
By allowing users to change key inputs, the
model is flexible enough to be useful to a vari-
ety of decision makers and can be used to
simulate various smoking cessation methods or
even new interventions. This flexibility also
extends to the model programme which was
designed as a database interacting with a visual
interface, which can be easily adapted should
any changes be required in the long term. For
example, it is anticipated that the model will
evolve so that it can be populated with new
epidemiology or cost data or extended to
include other countries as required. Internet
technologies have opened up more opportuni-
ties for information dissemination and by mak-
ing such models available over the web, a much
wider audience can be reached.
The OYce of Smoking and Health in the US
Public Health Service has also developed soft-
ware to permit rapid calculations of death,
years of potential life lost, direct health care
costs, indirect mortality costs, and disability
costs associated with cigarette smoking.19 20
The software, entitled SAMMEC (smoking
attributable mortality, morbidity, and econom-
ics costs), aims to provide the USA with data
onthehealthconsequencesofsmokingtopolicy-
makers and public health professionals. The
SAMMEC software has been further
developed and improved upon in recent
years,21–23 and has been used to calculate US
state estimates of Medicaid expenditures
attributable to cigarette smoking. The US
SAMMEC software has also been modified
and used to estimate smoking attributable
mortality in Mexico and Canada.24 25
By comparison, the HECOS model is an
interactive model, which looks at the current
smoking population in 25 countries and
predicts the cost and consequences of smoking
over a 20 year period for these populations.
Furthermore, HECOS allows users to input
and compare diVerent smoking cessation strat-
egies, at it is this feature which will be useful to
health care planners and policy makers.
One common argument against smoking
cessation is that it will increase health care
spending in the long term, as it increases life
expectancy and hence increases the lifetime
cost of health care. A controversial study by
Barendregt and colleagues concluded that if all
smokers quit, there would be savings in health
care costs, but only in the short term.26
However, such an argument can be applied to
any life extending intervention. The costs
should be oVset against any health gain, such
that the cost-eVectiveness of an intervention
should be considered. The authors themselves
state that public health policy is concerned
with health, and smoking therefore should be
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discouraged. In any case, it is true to say that
for a relatively small initial outlay, smoking ces-
sation interventions result in health gains,
which in the long term reduce the cost of
health care for smoking related diseases, releas-
ing resources for other health care
programmes.1 Some authors have questioned
the conclusion of the article by Barendregt and
colleagues, citing an underestimation of the
diVerences in costs and health care use
between smokers and non-smokers.27–31
Furthermore, studies in a number of countries,
including the USA, UK, Canada, and China,
do not support the notion that the tobacco
industry provides some national economic
benefit.32 It is felt that economic arguments in
support of tobacco consumption do not take
into account all of the associated costs or the
reduction in the quality of life of smokers. This
model evaluates the most visible costs
associated with tobacco and these indicate that
the economic burden of smoking is immense.
The authors are grateful for the contribution of the World
Health Organization “European partnership project to reduce
tobacco dependence”. This study was funded by Glaxo
Wellcome Inc. Dr Susan Hogue is a full time employee in the
Global Health Outcomes department at Glaxo Wellcome,
Research Triangle Park, NC, USA.
Appendix: model assumptions
CHANGES IN SMOKING BEHAVIOUR
At any time during their smoking career, people can
change their smoking habits and may temporarily or
permanently quit smoking. It is assumed that a smoker
can be in one of three smoking states, namely a current
smoker, a recent quitter or a long term quitter. Given
that most attempts to quit do not last for more than a
few days,33 we defined a long term quitter to be someone
who has not smoked for more than one year. Figure 1
shows the relation between the three smoking states in
this model.
EFFECT OF SMOKING CESSATION INTERVENTIONS
Cigarette craving and withdrawal symptoms will have
the most impact on those who have recently quit smok-
ing, and it is this group that will benefit most from
smoking cessation therapy. Therefore, in the model, it is
assumed that smoking cessation aids are targeted at
recent quitters and that withdrawal symptoms gradually
subside over time. Subsequently, smoking cessation
interventions increase the likelihood of a successful quit
attempt and long term quitters should have a lower
relapse rate compared to recent quitters. These
observations are shown in fig 2.
The impact of a one-oV investment in smoking
cessation was modelled by increasing the rate at which
smokers successfully quit for the first year of the model.
SMOKING AND HEALTH STATUS
Smokers are at risk from smoking related disease and
may die prematurely as a result. Ex-smokers can also
acquire smoking related diseases, but their risk of
disease will be less than that of a current smoker. Figure
3 shows how health status can change for a smoker or an
ex-smoker in the model. Note that the change from the
no morbidity state to the diseased state is assumed to be
irreversible.
The smoking related morbidities included in this
model were chronic obstructive pulmonary disease,
asthma, chronic heart disease, stroke, lung cancer, and
low birth weight pregnancies.
FORMULATION OF THE MODEL EQUATIONS
The model was constructed by considering the change
in the health status and smoking behaviour in the smok-
ing population over successive time steps of one year. In
general, smoking habits are stable33 and a shorter time
scale would not capture any change in smoking behav-
iour. Furthermore, disease and mortality rates are gen-
erally measured as a rate per year; therefore, a one year
time interval was considered to be the most suitable for
this model.
The smoking status of an individual in the model can
be split into three discrete (non-overlapping) states,
namely:
+ a current smoker;
+ a recent quitter (defined as an ex-smoker who has
quit for less than one year);
+ a long term quitter (defined as an ex-smoker who has
quit for more than one year).
Figure 1 Changes in smoking status.
Smoker
YES YES
NO
NO
NO
Recent
quitter
Long term
quitter
Starts smoking again?
Quits smoking
Smokes again
within 1 year?
Figure 2 EVect of cessation aid on smoking habit.
Smoker
Smoking
Cessation
Intervention
YES
NO
Recent
quitter
Long term
quitter
% of quitters
successful with
cessation aid > % of
quitters successful
without cessation aid
% of quitters relapsing
without cessation aid
% of quitters relapsing
with cessation aid
Smokes again
within 1 year?
Figure 3 Change of health status.
No
morbidity
Dead
YESYES
NO
Diseased
Dies from
disease?
Acquires disease?
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Furthermore, the health status of an individual can
also be split into three mutually exclusive states, namely:
+ no morbidity (healthy);
+ morbidity (not healthy but alive);
+ dead.
Altogether, an individual can be in one of seven
model states according to the smoking and health status
of that individual. Figure 4 gives a schematic represen-
tation of how an individual can move from one state to
another. Further schematic representations can be
found on eTC (www.tobaccocontrol.com). From this, it
can be seen that the number of individuals in a given
state Sj, at time t+1, depends on the number in
connected states at time t, that is:
The discrete diVerence equations used in the model
were constructed using equation 3, with the transition
from one state to another determined by the rate at
which smoking behaviour changes (that is, quit rates,
relapse rates), as well as disease and mortality rates. A
full list of the model equations can be obtained from the
author.
Death from non-smoking related causes are not cap-
tured in this model. This was because of an absence of
comprehensive data pertaining to the relation between
the development of smoking or non-smoking related
disease.
MODELLING DIRECT HEALTH CARE COSTS
For each year an individual is alive with a smoking
related disease, they will accumulate health care costs.
The model therefore estimates the cost of health care
associated with smoking related disease over a 20 year
period.
In general, people will prefer to have something
today, rather than at a future time—they have a “time
preference”. For example, we want the benefits today,
but the costs to occur later. As this model predicts costs
over 20 years, it is important to take into account the
eVect of time. In accordance with good economic prac-
tice, the future costs in this model were discounted to the
present time.34
From Drummond and colleagues35, if P is the present
value, Fn the future cost at year n, and r is the discount
rate, then future costs were discounted to the present
value using the formula:
MODELLING THE EFFECT OF AGE AND SEX
Smoking behaviour and disease risks will vary according
to age and sex. In general, more men smoke compared
to women and smoking prevalence is higher in younger
age groups. To capture this, the smoking population in
the model is split into a number of subpopulations
according to age and sex. The subpopulations
considered in this model were based upon the work of
Peto and colleagues36, with males aged 0–34, 35–69, and
70+, and females aged 0–34, 35–69, and 70+.
It is also noted that duration of smoking habit is a
better predictor of morbidity than level of smoking.33
Therefore, as the smoking population ages, the risk of
smoking related disease increases. Hence, in the model
the morbidity and mortality rates were time dependent
as well as dependent on age and sex.
MODELLING HEALTH GAINS RESULTING FROM SMOKING
CESSATION
In order to model the eVect of smoking cessation, the
interface runs two parallel calculations. In the first year
of the model, one calculation moves a number of smok-
ers from the recent quitters state to the long term quit-
ters state, according to the eYcacy of the smoking ces-
sation strategy chosen. The parallel calculation assumes
that the smoking cessation strategy did not take place.
The results in subsequent years are then compared to
ascertain the benefit of the incremental smoking cessa-
tion, which took place in the first year. This approach
takes into account those who would have quit smoking
anyway, and those who would have subsequently
relapsed.
The number of life years saved from a smoking
cessation intervention is calculated as follows:
+ those who die within model in year x, are said to have
survived for x − 1 model years;
+ those who survive to the end of the model run are
said to have survived 20 years;
+ the total number of years survived is: the number
who survive x years multiplied by x years, summed
over 20 years.
The number of life years saved through an interven-
tion is the diVerence in the total years survived with an
intervention, compared to the total life years survived
without an intervention.
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